The Chicago Department of Public Health and Northwestern University want to hear your ideas on how to get new HIV prevention medicine to sexual minority men (SMM) in Chicago. Top ideas will be selected for prizes.

In Chicago, HIV disproportionately affects SMM. To reduce HIV incidence among this key population, successful implementation of evidence-based practices is critical. Long-acting injectable cabotegravir (CAB-LA) offers a new form of HIV pre-exposure prophylaxis (PrEP) for prevention. Co-designing implementation strategies will maximize the likelihood of effective implementation of CAB-LA in Chicago. 

Focused on adolescent and adult SMM with particular attention to Black and Latino populations, this project deploys cutting-edge participatory methods that leverages input from target PrEP users in the community. 

Submit your ideas by May 27, 2024, at

This study is supported by a CFAR Ending the HIV Epidemic Supplement, “Crowdsourcing strategies for the implementation of long-acting injectable cabotegravir (CAB-LA) for HIV prevention for sexual minority men in Chicago” (PI: Amelia Van Pelt, PhD, Northwestern University; Implementation Partner: Jorge Cestou, PhD, Chicago Department of Public Health ).